UBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Medivation (NASDAQ: MDVN) to $142.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change FDA

Leerink Partners Reit OP Rating Following Medivation (MDVN) 1Q ResultsMay 8, 2015 9:45 AM Pre-Open Stock Movers 05/08: (WLT) (SYT) (SEDG) Higher; (KEYW) (PLNR) (SFM) Lower (more...)May 8, 2015 9:24 AM After-Hours Stock Movers 05/07: (NPTN) (SEDG) (DATA) Higher; (PLNR) (AVID) (SFM) Lower (more...)May 7, 2015 6:04 PM Medivation (MDVN) Misses Q1 EPS by 10cMay 7, 2015 4:17 PM Medivation Reports First Quarter 2015 Financial ResultsMay 7, 2015 4:10 PM